Chongqing Huapont Pharmaceutical Co., Ltd. was established in 1994 and is located in Liangjiang New District, Chongqing, China. It is a national high-technology, innovative, and intelligent model manufacturing enterprise. It has a national enterprise technology center and a number of municipal R&D platforms, two FDF factories, two API factories.


A new base of Huapont was officially completed and put into use


On September 19, 2022, the completion and commissioning ceremony of a new base was held, the new base is located in Changshou District, Chongqing. The construction of Changshou Base started on October 8, 2019, after 2 years and 11 months of construction, the total construction area 89036.79㎡ was completed, including four buildings for API, four buildings for storage warehouses, one building fro QC, one power center and one sewage treatment station. All plants are operated by gravity flow and equipped with automatic control systems such as DCS, SIS, BMS and WMS.

Huapont Pharma was awarded the 2021 Outstanding Company for National Adverse Drug Reaction Monitoring and Evaluation


The National Adverse Drug Reaction Monitoring Center commended Huapont Pharm. Due to its outstanding for performing the main responsibility. Meanwhile, Huapont Pharm. is also the only pharmaceutical manufacturer in Chongqing that has been commended. Under the leadership of the Drug Safety Committee

Huapont passed the NMPA GMP inspection for large-scale injection


From February 22 to February 25, 2022, and from March 1 to March 4, 2022, NMPA (National Medical Products Administration), Chongqing conducted on-site inspection for large-volume injection. The officers conducted a comprehensive inspection. including the R&D area and production site of the injection solution, specifically, the quality management and control at the site,